Earnings and Guidance Update Put CONMED Stock in Focus

CONMED (CNMD) drew fresh attention after reporting second quarter 2026 results, with net income and earnings per share higher than a year earlier and a modestly raised full year net sales outlook.

The latest earnings and modest guidance lift have come alongside a sharp shift in sentiment, with CONMED’s share price up 46.23% over the past month. However, the 1 year total shareholder return is still down 9.81%, and the 5 year total shareholder return is down 58.61%. Recent momentum therefore contrasts with a weak longer term record.

If CONMED’s move has you thinking about what else could be on your radar, this is a good moment to widen your search using our screener for 43 healthcare AI stocks

Bulls point to CONMED’s earnings progress and higher guidance. Bears focus on years of weak shareholder returns and a price that has just jumped. Which side does the current valuation really support next?

Most Popular Narrative: 24% Overvalued

CONMED’s latest close of $49.12 sits well above the most followed fair value estimate of $39.60, which is based on detailed long term earnings and cash flow modelling using a 9.09% discount rate.

The accelerating adoption of minimally invasive and robotic-assisted surgeries, combined with CONMED's strong positioning via AirSeal and BioBrace (including expanding use cases and positive clinical feedback), is poised to support durable procedure volume growth and increase recurring revenue, driving sustained top-line growth.

Want to see what kind of revenue path and margin shift would need to play out for CONMED to justify that gap between price and fair value? The narrative leans heavily on future earnings power, higher profitability, and how much investors might be willing to pay for those earnings a few years from now. If you are weighing the recent 46% share price jump against those long range assumptions, the full narrative lays out the numbers that connect today’s price to that $39.60 estimate.

Result: Fair Value of $39.60 (OVERVALUED)

However, CONMED’s story still carries clear risk, including ongoing supply chain pressures and heavy reliance on hospital capital budgets, which can quickly tighten.

Another View on CONMED: Multiples Paint a Different Picture

The DCF work suggests CONMED is trading well below an implied fair value of $106.95, yet the market is currently pricing the stock at a P/E of 26x. That is lower than the US Medical Equipment industry at 28.1x, the peer group at 33.9x, and the fair ratio of 32.1x. This gap points to potential valuation upside if sentiment shifted closer to those benchmarks, but it also raises a simple question for investors: Is the DCF too optimistic or are the market multiples too cautious?

Next Steps

After weighing both the recent optimism around CONMED and the longer term concerns, it makes sense to look at the underlying data yourself and move quickly to form your own view. A useful place to start is by checking the 3 key rewards and 3 important warning signs.

Looking for more investment ideas beyond CONMED?

If CONMED has sharpened your focus on valuations and risk, do not stop here. Broaden your opportunity set now so you are not reacting after the next move.

• Spot potential mispriced opportunities early by checking the 51 high quality undervalued stocks that pair quality fundamentals with appealing valuations.
• Prioritise resilience by scanning the 79 resilient stocks with low risk scores and concentrate your time on companies with more measured risk profiles.
• Hunt for under the radar potential using the screener containing 19 high quality undiscovered gems before the wider market pays attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.